Fennec Pharmaceuticals (FENC) Other Non-Current Liabilities (2010 - 2018)
Fennec Pharmaceuticals' (FENC) quarterly Other Non-Current Liabilities came in at $167000.0 in Q2 2018, up 206.37% YoY from $54509.4 in Q2 2017, and little changed on a QoQ basis from $167000.0 in Q4 2017.
Fennec Pharmaceuticals (FENC) Other Non-Current Liabilities (2010 - 2018) Analysis & Trends
Fennec Pharmaceuticals (FENC) has 9 years of Other Non-Current Liabilities data on file, last reported at $167000.0 in Q2 2018.
- Quarterly Other Non-Current Liabilities rose 206.37% year-over-year to $167000.0 in Q2 2018, while the trailing twelve-month figure through Jun 2018 was $167000.0 (up 206.37% YoY) and the FY2017 annual result came in at $167000.0, up 406.06% from the prior year.
- Other Non-Current Liabilities was little changed at $167000.0 in Q2 2018, from $167000.0 in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $5.5 million in Q1 2014 to a low of -$157000.0 in Q2 2017.
- A 5-year average of $1.2 million and a median of $167000.0 in 2017 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2014 — Other Non-Current Liabilities jumped 2342.59% — and 2015, when it plunged 97.34%.
- Tracing FENC's Other Non-Current Liabilities over 5 years: stood at $1.3 million in 2014, then plunged by 93.78% to $82000.0 in 2015, then slumped by 59.76% to $33000.0 in 2016, then surged by 406.06% to $167000.0 in 2017, then changed by 0.0% to $167000.0 in 2018.
- The last three Other Non-Current Liabilities figures came in at $167000.0 (Q2 2018), $167000.0 (Q4 2017), and -$157000.0 (Q2 2017), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Fennec Pharmaceuticals | 410.60 Mn | 369.35 Mn | 17.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2018 | 167,000.00 |
| Dec 31, 2017 | 167,000.00 |
| Jun 30, 2017 | -157,000.00 |
| Mar 31, 2017 | 71,000.00 |
| Dec 31, 2016 | 33,000.00 |
| Mar 31, 2016 | 39,000.00 |
| Dec 31, 2015 | 82,000.00 |
| Sep 30, 2015 | 93,000.00 |
| Jun 30, 2015 | 309,000.00 |
| Mar 31, 2015 | 694,000.00 |
| Dec 31, 2014 | 1.32 Mn |
| Sep 30, 2014 | 3.50 Mn |
| Jun 30, 2014 | 5.34 Mn |
| Mar 31, 2014 | 5.52 Mn |
| Dec 31, 2013 | 54,000.00 |
| Dec 31, 2012 | 96,000.00 |
| Dec 31, 2011 | 108,000.00 |
| Dec 31, 2010 | 86,000.00 |